This study will evaluate the efficacy of SBR759 compared to sevelamer HCl in lowering serum phosphate levels in Chronic Kidney Disease patients on hemodialysis

Inclusion criteria

• Men or women of at least 18 years old.
• Stable maintenance of renal replacement therapy 3 times per week.
• Controlled Serum phosphate if under phosphate-binder therapy.
• Serum phosphate level ≥ 6.0 mg/dL (> 1.9 mmol/L) prior to study treatment initiation.

Exclusion criteria

• Peritoneal dialysis.
• Parathyroidectomy or transplant scheduled during the study.
• Uncontrolled hyperparathyroidism
• History of hemochromatosis or ferritin > 1000 µg/L.
• Clinically significant GI disorder
• Unstable medical condition other than Chronic Kidney Disease.
• Treated with oral iron.
• Other protocol-defined inclusion/exclusion criteria may apply.